Source: Pharmacy Times articles
New research uncovers the complex tumor microenvironment in multiple myeloma, revealing unique plasma cell ecosystems that challenge existing treatment approaches.
Recent Content
- Bone Marrow Microenvironments Vary Widely in Multiple Myeloma, Study Finds
- Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis
- Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
- Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’
- Future Perspectives in Multiple Myeloma
- Patients and Caregivers Aim to Raise Funds for Myeloma Research
- GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
- Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
- Blood Test Could Replace Bone Marrow Biopsies in Multiple Myeloma
- Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis